{"id":"NCT00483652","sponsor":"Acorda Therapeutics","briefTitle":"Study of Fampridine-SR Tablets in Multiple Sclerosis Patients","officialTitle":"Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05","primaryCompletion":"2008-02","completion":"2008-05","firstPosted":"2007-06-07","resultsPosted":"2011-04-14","lastUpdate":"2016-02-04"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Fampridine-SR","otherNames":["4-aminopyridine"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Fampridine-SR","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to show that individuals treated with Fampridine-SR tablets are significantly more likely to have consistent improvements in their walking than those treated with placebo tablets.","primaryOutcome":{"measure":"Responders Based Upon the Timed 25-Foot Walk [T25FW]","timeFrame":"Days -21, -14, -7, 0, 14, 28, 42, 56, 63, 77","effectByArm":[{"arm":"Fampridine-SR 10 mg b.i.d. Treatment","deltaMin":51,"sd":null},{"arm":"Placebo Treatment","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":40,"countries":["United States","Canada"]},"refs":{"pmids":["20976768"],"seeAlso":["http://www.acorda.com/clinical.asp"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":120},"commonTop":["Fall","Urinary tract infection","Asthenia","Upper respiratory tract infection","Insomnia"]}}